EEG Encephalopathy Patterns in Immune Effectors Cells-associated Neurotoxicity Syndrome (ICANS)Lay Language
NCT05040230 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2022-04-12
Summary
Immune effectors cells-associated neurotoxicity syndrome (ICANS) is one of the most clearly defined acute toxicities after CAR-T cells infusion.
The investigators conducted a prospective cohort study of all patients who received CAR T cell infusions on the hematology department from Montpellier University Medical Center.
Each patient was assessed between the 6th and 8th day after infusion by a neurological clinical examination, an electroencephalogram, and a brain MRI.
The aim of the studies is to describe the EEG pattern associated with ICANS.
Conditions
- Immune Effector Cell Encephalopathy
- Neurotoxicity
Sponsors & Collaborators
-
University Hospital, Montpellier
lead OTHER
Principal Investigators
-
Xavier Ayrignac, MD · University Hospital, Montpellier
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-02-01
- Primary Completion
- 2021-12-01
- Completion
- 2021-12-30
Countries
- France
Study Locations
More Related Trials
-
Change of Nerve Conduction Properties in IVIg Dependent Neuropathies
NCT01655394 ·Status: UNKNOWN
-
A Study of Galcanezumab in Healthy Participants.
NCT02836613 ·Status: COMPLETED ·Phase: PHASE1
-
Isatuximab in Type I Cryoglobulinemia
NCT05114109 ·Status: UNKNOWN ·Phase: PHASE2
-
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
NCT04146051 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
NCT07039916 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of LY3016859 in Healthy Volunteers
NCT01545583 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY3079514 in Healthy Participants
NCT02242903 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers
NCT03146416 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms
NCT00487708 ·Status: COMPLETED ·Phase: PHASE2
-
Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease
NCT02770625 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
NCT02473965 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
NCT07265206 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders
NCT05891379 ·Status: RECRUITING
-
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
NCT04124965 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Galcanezumab in Healthy Participants
NCT02576951 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Imlifidase in Patients With Guillain-Barré Syndrome
NCT03943589 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:
NCT04175522 ·Status: COMPLETED ·Phase: PHASE2
-
Markers of Favorable Response to FcRn Inhibitors(INFORM)
NCT06685055 ·Status: RECRUITING
-
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
NCT03971422 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease
NCT05728684 ·Status: UNKNOWN ·Phase: NA
-
Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)
NCT02650895 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
NCT04875975 ·Status: TERMINATED ·Phase: PHASE2
-
Canakinumab for Treatment of Adult-onset Still's Disease
NCT02204293 ·Status: TERMINATED ·Phase: PHASE2
-
Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome
NCT00004833 ·Status: TERMINATED ·Phase: NA
-
A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
NCT02473952 ·Status: COMPLETED ·Phase: PHASE2